GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SkinBioTherapeutics PLC (LSE:SBTX) » Definitions » Growth Rank

SkinBioTherapeutics (LSE:SBTX) Growth Rank : 0 (As of Jun. 14, 2024)


View and export this data going back to 2017. Start your Free Trial

What is SkinBioTherapeutics Growth Rank?

SkinBioTherapeutics has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.


SkinBioTherapeutics Growth Rank Related Terms

Thank you for viewing the detailed overview of SkinBioTherapeutics's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


SkinBioTherapeutics (LSE:SBTX) Business Description

Traded in Other Exchanges
N/A
Address
Bath Lane, The Core, Newcastle Helix, Newcastle upon Tyne, GBR, NE4 5TF
SkinBioTherapeutics PLC is a life science company focused on skin health. It is focused on the development of technology to protect, manage, and restore skin utilizing proteins found in the human microbiota. It is targeting three specific skin healthcare sectors; cosmetics, infection control, and eczema.

SkinBioTherapeutics (LSE:SBTX) Headlines

From GuruFocus

ARS Pharmaceuticals Closes Merger with Silverback Therapeutics

By Value_Insider Value_Insider 11-08-2022